Cancer and stilbestrol. A follow-up of 1,719 persons exposed to estrogens in utero and born 1943-1959.
D000230:Adenocarcinoma / Q000139:chemically induced; D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D004054:Diethylstilbestrol / Q000009:adverse effects*; D004967:Estrogens / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008431:Maternal-Fetal Exchange; D008910:Minnesota; D009369:Neoplasms / Q000139:chemically induced*; D011247:Pregnancy; D011374:Progesterone / Q000009:adverse effects; D011446:Prospective Studies; D014565:Urogenital Neoplasms / Q000139:chemically induced*; D002583:Uterine Cervical Neoplasms / Q000139:chemically induced; D014625:Vaginal Neoplasms / Q000139:chemically induced
D004967:Estrogens; D011374:Progesterone; D004054:Diethylstilbestrol